ALBERTA PRECISION LABORATORIES

Leaders in Laboratory Medicine

DATE:	28 April 2025	
TO:	South Zone – All Physicians, Nurses and Managers	
FROM:	Clinical Biochemistry, Alberta Precision Laboratories (APL)	
	Implementation of High Sensitivity Troponin I (hs-TnI) on the Quidel TriageTrue with 2-hr Chest Pain Pathway in Rural Sites	

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- Effective April 30, 2025, implementation of a new high sensitivity troponin I (hs-TnI) assay on the Quidel TriageTrue will begin across 9 rural hospitals in the South Zone (Table 1).
 - NOTE: The South Zone sites of Bassano, Bow Island and Oyen are to follow at a later date.

Table 1. TriageTrue high sensitivity troponin I method implementation timeline

Bassano	To be determined (~May-June 2025)
Bow Island	To be determined (~May-June 2025)
*Brooks	April 30, 2025
*Cardston	April 30, 2025
Coaldale	April 30, 2025
Crowsnest Pass	April 30, 2025
Fort MacLeod	April 30, 2025
Milk River	April 30, 2025
Oyen	To be determined (~May-June 2025)
*Pincher Creek	April 30, 2025
*Raymond	April 30, 2025
*Taber	April 30, 2025

*Backup assay to the primary Beckman Access 2 assay

- Sites using the TriageTrue hsTnI assay will offer the new 2-Hour Chest Pain Pathway for Quidel TriageTrue High Sensitivity Troponin-I Assay (Appendix 1).
- The TriageTrue hs-Tnl assay requires sample collection in lavender EDTA blood collection tubes.

No other sample collection tubes are acceptable.

- o For additional information refer to the APL reference: Order of Draw and Order of Transfer
- This troponin assay change will involve new: units of measure, reference interval (i.e. 99th percentile upper reference limit of the assay), reporting limits, rule-in/rule-out chest pain pathway, delta values, critical limits and interpretative comments (Table 2).
- At sites with the TriageTrue hs-TnI assay, critical troponin concentrations (≥ 60 ng/L) will be phoned to the ordering provider <u>ONLY</u> for troponin samples collected in the outpatient/community setting.
 - Lab will **<u>not</u>** phone troponin results for hospital patients (including ER patients and inpatients).



Background

- Evidence supports that a 2-hour chest pain pathway for TriageTrue hs-Tnl is effective and safe for rule-in/rule-out of acute myocardial infarction (AMI).
- The recommended pathway is consistent with clinical practice guidelines and is recommended by the Cardiovascular Program Improvement and Integration Network (PIN) in consultation with Emergency Medicine PIN and Laboratory Medicine provincially.

Why this is important

- The provincial rural immunoassay analyzer project is a large-scale provincial project that will improve access to vital laboratory testing in many of Alberta's rural hospitals and will improve standardization in instrumentation and reporting.
- Adoption of the 2-hour hs-Tnl chest pain pathway with rapid rule-in/rule-out is gradually expanding across the province and improving flow of patients through emergency rooms.
- This initiative will reduce the variation of troponin assays and chest pain protocols in the province.
- These changes will assist clinicians with evidence-based interpretation of troponin results and guide optimal patient management.

Action Required

- Collect samples for TriageTrue hs-Tnl in lavender EDTA tubes
- Be familiar with changes in assay reporting, container type and the new 2 hr chest pain pathway.
- Be aware of different troponin assays used within the South Zone.
- Do not interpret results across sites with different assays.

Questions/Concerns

- Dr. Heather Paul, Clinical Biochemist, South Sector, APL | <u>heather.paul@aplabs.ca</u>
- Cardiovascular PIN <u>CardiovascularPIN@acutecarealberta.ca</u>

Approved by

- Dr. Allison Venner, Clinical Biochemistry Section Chief, South Sector, APL
- Dr. Krishna Narra, Associate Medical Director, Rural, South Sector, APL



Table 2: Summary of new reporting changes for the TriageTrue hs-Tnl assay

	i-STAT conventional Tnl (Current)	Cobas h232 conventional TnT (Current)	TriageTrue hs-Tnl 2- hr Chest Pain Pathway (New)	Notes
Collection Tube	Lithium heparin PST (light green)	Lithium heparin PST (light green) or Sodium heparin (dark green)	Lavender EDTA	
Rapid Chest Pain Pathway	N/A	N/A	2-hour	
Reporting Units	ug/L (2 decimals)	ug/L (3 decimals)	ng/L (whole number)	
Reference Interval	<0.04 ug/L	<0.040 ug/L	< 21 ng/L	
Critical Value	>0.10 ug/L	>0.100 ug/L	≥ 60 ng/L	
Reporting Limits	0.02 to 50 ug/L	0.040 to 2.000 ug/L	2 to 1000 ng/L	
Delta Value	None	None	Reported for 0-2 hour delta	
Comments	Interpretive comments And Method identification comments	Interpretive comments And Method identification comments	Pathway interpretative comments And Method identification comments	Interpretative comments have changed (Table 3)



Table 3: Interpretative comments reported with Quidel TriageTrue hs-Tnl

hs-Tnl result (ng/L)	Comment	Flagging
< 4	 For patients with a non-ischemic ECG, a Troponin I, High Sensitivity of 3 ng/L or less on presentation is highly sensitive for excluding acute myocardial infarction, provided the specimen was collected more than 3-hours from symptom onset. However, for patients with symptoms less than 3-hours duration or concerning clinical presentations, repeat troponin testing at 2-hours after the initial sample is recommended. Please note that patients with ischemic ECG changes and/or highrisk clinical presentations should be considered for further evaluation irrespective of troponin results. 	Normal
4 – 20	 Troponin I, High Sensitivity is below the upper reference limit (21 ng/L) and results are not consistent with myocardial infarction (MI) or injury. However, patients with acute symptoms (less than 6-hours) or concerning clinical presentations should undergo repeat troponin testing at 2-hours after the initial sample. Troponin I, High Sensitivity of 4 ng/L or less on presentation AND a 2-hour delta(change) of 2 ng/L or less is highly sensitive for excluding acute myocardial infarction (MI) A 2-hour delta (change) of 3-7 ng/L may indicate acute myocardial injury and suggest an additional troponin measurement 4 hours after the initial sample, serial ECG testing and clinical re-evaluation. A 2-hour delta (change) of 8 ng/L or more suggests an acute myocardial injury and may represent acute myocardial infarction in the appropriate clinical scenario. 	Normal
21 – 59	 evaluation irrespective of troponin results Troponin I, High Sensitivity has a non-specific/non-diagnostic elevation. Interpretation is highly dependent on clinical presentation and patient history. New elevations are concerning; however, many patients have chronic elevations in troponin and measured concentrations near the patient's baseline are reassuring. However, patients with acute symptoms (less than 6-hours) or concerning clinical presentations should undergo repeat troponin testing at 2-hours after the initial sample. A 2-hour delta (change) of 2 ng/L or less is highly sensitive for excluding acute myocardial infarction. A 2-hour delta (change) of 3-7 ng/L may indicate acute myocardial injury and suggest an additional troponin measurement 4 hours after the initial sample, serial ECG testing and clinical re-evaluation. 	High




Leaders in Laboratory Medicine

	Please note that patients with ischemic ECG changes and /or high- risk clinical presentations should be considered for further evaluation irrespective of troponin results	
60	Clear elevation of Troponin I, High Sensitivity consistent with acute myocardial injury or infarction in the appropriate clinical context Repeat troponin testing at 2-hours after the initial sample may be helpful to assess for ongoing myocardial injury	Critical



Appendix 1: 2-Hour Chest Pain Pathway for Quidel TriageTrue High Sensitivity Troponin-I Assay





Note:

*For all patients with abnormal hs-cTnl results, check the medical record for prior results. Many patients have stable abnormalities in hs-cTnl and measured concentrations similar to the patient's baseline are reassuring.

Per European Society of Cardiology (ESC) Guidelines and 4th universal definition of MI, if the patient is >6h from symptom onset, has a hs-cTnI <21 ng/L (99th percentile upper reference limit), are pain-free, and have a low-risk presentation, they can be considered ruled out.

However, coronary ischemia has not been definitively excluded and unstable angina must be considered. Disposition after a single hs-cTnI <21 ng/L should only be considered for patients with low-risk clinical presentations who are >6 hours since symptoms onset, and should be used cautiously.

Troponin concentration may be elevated in the presence of kidney dysfunction. Patients with an eGFR <60 and an elevated troponin concentration should undergo serial testing to confirm a rising troponin concentration consistent with myocardial injury. Patients with an eGFR <60 who have troponin concentrations in the rule-out zone can be considered to have myocardial injury safely excluded.

HEART Score Calculation				
		Highly suspicious	2	
History		Moderately suspicious	1	
	Slightly suspicious		0	
	Significant ST-depression		2	
ECG	Non-specific repolarization disturbance, LBBB, LVH, Paced		1	
		Normal	0	
	≥ 65 years		2	
Age	45-64 years		1	
	≤ 44 years		0	
	Diabetes	≥ 3 risk factors or history of atherosclerotic disease	2	
Risk	Obesity	1 or 2 risk factors	1	
Factors	☐ Family hx CAD ☐ HTN (diagnosed) ☐ HL (diagnosed)	No risk factors known	0	
hs-cTnl	> 3x normal limit (64 ng/L or greater)		2	
(peak)	1-3x normal limit (21-63 ng/L)		1	
(peak)	< normal limit (< 21 ng/L)		0	
		Total (10 maxi	mum)	
	HEART Sc	ore Interpretation		
Low Risk			0-3	
Moderate Risk			4-6	
High Risk				7-10